MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-09-2022
Epizyme Total Assets 2011-2025 | EPZM
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 289 M | 474 M | 425 M | 276 M | 289 M | 252 M | 218 M | 199 M | 163 M | 104 M | 37.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 474 M | 37.4 M | 248 M |
Quarterly Total Assets Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 264 M | 312 M | 289 M | 332 M | 353 M | 407 M | 474 M | 474 M | 474 M | 474 M | 425 M | 425 M | 425 M | 425 M | 276 M | 276 M | 276 M | 276 M | 289 M | 289 M | 289 M | 289 M | 252 M | 252 M | 252 M | 252 M | 218 M | 218 M | 218 M | 218 M | 199 M | 199 M | 199 M | 199 M | 163 M | 163 M | 163 M | 163 M | 104 M | 104 M | 104 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 474 M | 104 M | 279 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M |  USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
144 M | $ 4.72 | 0.96 % | $ 783 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
220 M | $ 3.32 | -1.19 % | $ 257 M | USA |
 |
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.58 B | $ 25.26 | -2.47 % | $ 1.22 B | USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
283 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
608 M | - | - | $ 1.01 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
1.18 B | $ 209.93 | -0.11 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M |  Israel |
 |
Aptorum Group Limited
APM
|
16.1 M | $ 1.31 | -1.88 % | $ 7.14 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.4 | -0.71 % | $ 8.18 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
AstraZeneca PLC
AZN
|
104 B | $ 89.77 | -0.57 % | $ 96.9 B | Britain |
 |
Anika Therapeutics
ANIK
|
271 M | $ 9.59 | 1.05 % | $ 141 M | USA |
 |
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
5.92 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
23.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
226 M | - | -7.31 % | $ 87 M | USA |
 |
Biogen
BIIB
|
28 B | $ 174.05 | 0.9 % | $ 25.3 B | USA |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.33 | 2.08 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
10 M | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | USA |
 |
Benitec Biopharma
BNTC
|
99.6 M | $ 12.26 | -5.4 % | $ 505 M | USA |
 |
BioNTech SE
BNTX
|
22.5 B | $ 94.78 | -1.28 % | $ 27.2 B |  Germany |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
68.3 M | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
4.47 B | $ 570.12 | -1.88 % | $ 43.2 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.12 M | $ 0.28 | -2.76 % | $ 609 M | Israel |
 |
Catalyst Biosciences
CBIO
|
117 M | $ 14.66 | -4.25 % | $ 965 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
7.47 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
35 M | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
473 M | - | -7.23 % | $ 13 M | USA |
 |
BioVie
BIVI
|
21.6 M | $ 1.47 | -2.55 % | $ 2.17 M | USA |
 |
Cortexyme
CRTX
|
168 M | - | -1.05 % | $ 67.1 M | USA |
 |
Celldex Therapeutics
CLDX
|
792 M | $ 27.54 | -1.43 % | $ 1.77 M | USA |
 |
Cellectar Biosciences
CLRB
|
12.1 M | $ 3.61 | -4.5 % | $ 44.1 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
474 M | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.08 B | $ 11.3 | -1.22 % | $ 731 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
21.1 M | - | -5.68 % | $ 8.28 M | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Enochian Biosciences
ENOB
|
8.23 M | - | - | $ 40.5 M | USA |
 |
Cerus Corporation
CERS
|
201 M | $ 2.15 | -0.23 % | $ 397 M | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |